Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
drugs
4
×
life sciences
national blog main
patisiran
4
×
akcea therapeutics
alnylam pharmaceuticals
boston
clinical trials
fda
inotersen
national top stories
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
tafamidis
hereditary transthyretin amyloidosis
pfizer
rna interference
acute hepatic porphyrias
akin akinc
aminolevulinic acid
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
dan ollendorf
european medicines agency
givosiran
harvard pilgrim health care
institute for clinical and economic review
john berk
mary o'donnell
neuropathy
new york
paul matteis
What
alnylam
fda
ago
drug
medicine
rna
interference
patients
rnai
uses
akcea
amyloidosis
approval
approve
approved
approves
attr
available
awaits
battle
biological
cells
crossed
debilitating
decades
decision
discovered
disease
ema
employ
europe
fingers
follows
friday
gene
genetic
harmful
historic
hits
indicated
Language
Current search:
patisiran
×
drugs
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision